TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Hydroxychloroquine for the First Thrombosis Prevention in Antiphospholipid Antibody Positive Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Persistent(at least 12 weeks apart)aPL-positivity within 12 months prior to the screening defined as:~  * aCL IgG/M (\>40U,medium-to-high titer,and/or greater than the 99th percentile)and/or~ * aβ2GPI IgG/M(\>40U, medium-to-high titer, and/or greater than the 99th percentile)and/or~ * Positive LA test based on the International Society of Thrombosis \& Haematosis Recommendations~Selected Exclusion Criteria:~* History of thrombosis (arterial, venous, and/or biopsy proven microthrombosis~* History of Transient Ischemic Attack Confirmed by a Neurologist~* SLE Diagnosis based on the ACR Classification Criteria \> 4/11~* Other Systemic Autoimmune Diseases diagnosed based on ACR Classification Criteria~* Current Hydroxychloroquine or another antimalarial treatment (-3 months)~* Current warfarin treatment (-3 months)~* Current heparin therapy( -3 months)~* Current pregnancy~* History of Hydroxychloroquine eye toxicity~* History of Hydroxychloroquine allergy~* Known glucose-6-phosphate dehydrogenase deficiency

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Standard treatment (Type: NO_INTERVENTION): patients randomized to standard treatment will not receive hydroxychloroquine.
- Hydroxychloroquine (Type: EXPERIMENTAL): Patients will be randomized to receive standard of care or standard of care + hydroxychloroquine. Dose will be weight-adjusted: 200 mg daily for patients weighing \<60kg; and 400 mg daily (200 mg twice a day)for patients weighing \>60kg.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: An Evaluation of the Ability to Train Established Glaucoma Patients Who Have Difficulty in Drop Instillation

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients aged 18 years or older~* Patients currently using topical ocular antihypertensive medications at the time of enrollment in at least one eye, and who have been using these drops consistently for a period of at least three months prior to enrollment.~* Patients with primary open angle glaucoma, pigmentary glaucoma, exfoliation glaucoma, ocular hypertension, normal-tension glaucoma, neovascular glaucoma, uveitic glaucoma and chronic narrow angle glaucoma.~* Patients CAN be enrolled even if they have co-existing morbidities such as Parkinson's Disease or arthritis~Exclusion Criteria:~* Patients who do not instill their own eye drops~* Patients who are not expected to still be using topical antihypertensive medications at the time of study follow-up~* Patients with no light perception vision~* Patients with a history of adverse reaction to artificial tears or any component of artificial tears~* Patients who have a typical follow-up period of greater than 6 months~* Patients who have not completed a Humphrey Visual Field C24-2 or C10-2 within 7 months of enrollment or study exit.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: PTK787 + Trastuzumab for HER2 Overexpressing Metastatic Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologic or cytologic diagnosis of breast cancer with evidence of measurable (1) unresectable, locally recurrent, or (2) metastatic disease. Locally recurrent disease must not be amenable to resection OR radiation with curative intent.~* Patient's disease may not involve more than 3 metastatic sites. In addition, patient may not be symptomatic from pulmonary metastasis or have liver metastasis involving \> 50% of parenchyma.~* HER2 gene amplification by FISH. HER protein overexpression by immunohistochemistry will not be sufficient for entry.~* Negative pregnancy test~Exclusion Criteria:~* No prior cytotoxic chemotherapy or trastuzumab for locally recurrent or metastatic disease.~* No prior treatment with any VEGF inhibiting agents~* No history or presence of central nervous system (CNS) disease.~* No other forms of cancer therapy including radiation, chemotherapy and hormonal therapy within 21 days prior to being registered for protocol therapy.~* No major surgery within 28 days prior to being registered for protocol therapy.~* No uncontrolled hypertension (SBP \> 170, DBP \> 90), history of labile hypertension or history of poor compliance with antihypertensive therapy.~* No requirement for therapeutic anticoagulation, regular aspirin (\> 325 mg/day) or NSAID use.~* No current breast feeding.~* No impairment of gastrointestinal (GI) function that may significantly alter the absorption of PTK787.~* No evidence of other serious concomitant systemic disorders incompatible with the study (at the discretion of the investigator).

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Single Group Assignment (Type: EXPERIMENTAL): Trastuzumab + PTK787 for HER2 positive patients

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Improving Mental and Physical Health and Decreasing Hospital Readmission After Pancreatectomy Through Enhanced Patient and Caregiver Education and Engagement

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Scheduled for major pancreatectomy (i.e., pancreaticoduodenectomy, total pancreatectomy, or a distal pancreatectomy).~* At least 18 years of age.~* Able to read and understand English (the SAFECARE at Home program is only implemented in English)~* Has internet access.~* Knowledge of the internet and how to use web-based programs.~* Not pregnant or breastfeeding.~* Able to understand and willing to sign an IRB-approved written informed consent document.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1: SAFECARE at Home (Type: EXPERIMENTAL): * Patients randomized to the intervention arm will be assigned a username and password to access a SAFECARE at Home account via the internet. They will also be emailed a link to the site with their username and password.~* The investigators have worked directly with SAFECARE at Home to create customized lessons for patients undergoing pancreatectomy. These lessons are comprehensive and encompass preoperative preparation as well as postoperative recovery and care. This includes videos, printed material, web-based material, and modules that focus on the pre-treatment, treatment, and follow-up care of patients undergoing surgery for pancreatic cancer.~* All patients will receive standard pre- and post-operative instructions and care. This will include verbal education about the procedure by the surgeon as well as standard educational patient handouts, which are routinely provided preoperatively to pancreatectomy patients.
- Arm 2: Standard of Care (Type: NO_INTERVENTION): -All patients will receive standard pre- and post-operative instructions and care. This will include verbal education about the procedure by the surgeon as well as standard educational patient handouts, which are routinely provided preoperatively to pancreatectomy patients.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Phase 2b Study of GC4711 in Combination With SBRT for Nonmetastatic Pancreatic Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Histological or biopsy proven adenocarcinoma of the pancreas. Cytology is acceptable if histology cannot be obtained.~2. Newly diagnosed non-metastatic PC judged by tumor board to be feasible for SBRT~3. Completed at least 6 weeks of chemotherapy consisting of FOLFIRINOX, mFOLFIRINOX, or a gemcitabine-based doublet regimen prior to start of SBRT~4. Remain non-metastatic as confirmed by a CT scan at screening.~5. Female or male subjects ≥ 18 years of age~6. ECOG performance status of 0-2~7. Adequate end-organ function~Exclusion Criteria:~1. Subjects with documented metastatic disease~2. First-line chemotherapy other than FOLFIRINOX, mFOLFIRINOX, and/or a gemcitabine-based doublet regimen~3. Prior abdominal RT with substantial overlap in radiation fields~4. Subjects not recovered/controlled from treatment-related toxicities~5. Uncontrolled malignancy other than PC~6. Uncontrolled gastric or duodenal ulcer disease within 30 days of dosing~7. Visible invasion of bulky tumor into the lumen of the bowel or stomach on endoscopy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A Active GC4711 (Type: EXPERIMENTAL): None
- Arm B Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Acupuncture in Stroke Rehabilitation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* After stroke (\>6 months)~Exclusion Criteria:~* Other neurological diseases

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Acupuncture and strength training
- 2 (Type: OTHER): Strength training

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: The Use of Alpha Lipoic Acid for the Treatment and Prevention of Diabetic Retinopathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Individual with diabetes mellitus type I or type II mild to moderate non-proliferative diabetic retinopathy which will be based on ETDRS grading scale~* Patient must be 18 years and older~Exclusion Criteria:~* Patients with severe non-proliferative or proliferative diabetic retinopathy~* Patients with macular edema~* Eye diseases that may interfere with visualization of the fundus such as preretinal hemorrhage, cataract, vitreous hemorrhage~* Patient that has undergone any type of interventional therapy for diabetic retinopathy (Such as laser photocoagulation, vitrectomy)~* Amblyopia~* Glaucoma~* Patient with cataract surgery within a period of 4 months~* Patients with other retinal diseases~* Patients on chronic administration of alpha lipoic acid~* Known intolerance/hypersensitivity to alpha lipoic acid~* Patient with history of dialysis in cases of renal insufficiency and history of kidney transplantation~* Malignancies or life threatening diseases as determined by the investigators~* Current history of drug or alcohol abuse~* Pregnant and breast feeding women~* Cognitively impaired patients~* Participation in a clinical trial within the last 30 days

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Alpha Lipoic Acid Assignment Group (Type: EXPERIMENTAL): Alpha lipoic acid assignment group will follow routine care and receive 600 mg oral administration of lipoic acid daily.
- Alpha Lipoic Acid Control Group (Type: NO_INTERVENTION): The control group will follow routine care alone.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Early Parkinson's Disease (PD) Cross-Sectional

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. 35-80 year old men \& women~2. Patients with iPD or Parkinsonian syndromes, or controls consisting of healthy subjects, or subjects who have a non-neurodegenerative diagnosis but are otherwise healthy.~3. Gives written informed consent~4. Pregnant women are not excluded, but will be identified by HCG.~Exclusion Criteria:~1. Parkinsonian symptoms not due to idiopathic (sporadic) PD, such as those that are medication induced, toxic substance induced or representative of an atypical Parkinsonian syndrome will be categorized separately.~2. Any unstable or uncontrolled medical or psychiatric condition.~3. Renal (creatinine over 1.6) or hepatic insufficiency (LFT three-fold higher than normal range), or a history of significant cardiac disease.~4. If there is a history or evidence of coagulopathy, on medications such as Plavix, Aggrenox, heparin, coumadin, or large doses of aspirin, must be able to remain off these medications for at least 3 days, and have stable blood coagulation values prior to any lumbar puncture (LP).~5. Significant dementia (MMSE\<25/30 or MOCA\<25/30) that would interfere with study procedures or the giving of informed consent for the study .~6. Active infections including skin, respiratory or GI infections, and HIV+ (if undergoing an LP).~7. Any evidence of a different neurodegenerative disorder, for example, Alzheimer's Disease or Huntington's Disease.~8. fMRI will not be performed is screening questionnaire identifies a reason.

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: None): Clinically diagnosed Early iPD
- 2 (Type: None): Age/gender matched controls without neurodegenerative diagnosis
- atypical or late Parkinsonian Syndromes (Type: None): Includes subjects facing or having undergone DBS, diagnoses of MSA, PSP or other atypical syndromes.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Omega-3 Fatty Acids Supplementation in ADHD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Participants between ages 6 and 12 years who:~1. have been clinically diagnosed with ADHD by a physician~2. meet the criteria of ADHD-Inattention, ADHD-Hyperactivity-Impulsivity, or ADHD-Combined type as determined by the SNAP-IV (Swanson, 1992)~3. are willing to participate in a randomized, double-blind, placebo-controlled trial, complete with written, informed parental consent,~4. are on stable dosage of methylphenidate treatment before the start of the study~5. are able to speak English or German~Exclusion Criteria:~1. Participants who are younger than 6 years old or older than 12 years old~2. Those who have not been clinically diagnosed with ADHD by a physician~3. Those who did not meet the criteria of ADHD-Inattention, ADHD-Hyperactivity-Impulsivity, or ADHD-Combined type as determined by the SNAP-IV (Swanson, 1992)~4. Those without written parental consent~5. Those with brain pathology such as serious head injury, epilepsy, and intellectual disability (IQ \< 70)~6. Those with titrated dosage of methylphenidate before the start of the study~7. Those on neurofeedback training, and/or psychosocial intervention addressing attention problems~8. Those with known hypersensitivity to the IMP under investigation~9. Those who are unable to read and understand the parent/participant information~10. Those receiving medications other than methylphenidate

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- Omega-3 Fatty Acids (Type: EXPERIMENTAL): 1g of Omega-3 per day \[400mg DHA \& 600mg EPA\] for 12 weeks: 2 capsules after breakfast and 2 capsules after dinner
- Omega-3 Placebo (Type: PLACEBO_COMPARATOR): 1g of Omega-3 Placebo per day for 12 weeks: 2 capsules after breakfast and 2 capsules after dinner

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Food Frequency Questionnaire for Chinese Pregnant Women

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Should be Hong Kong Chinese citizen~* Should reside normally in Hong Kong~* Age at or above 18 years old~* With antenatal registry in the study hospital~* Singleton pregnancy~* Gestational age of 5 weeks or above~* Could speak and understand Chinese~* Willing to follow the study procedures~Exclusion Criteria:~* Currently participating in any clinical trial or trial with dietary intervention~* Multiple pregnancy~* With any renal, liver or thyroid dysfunction, any other indication of a major medical or psychological illness, as judged by the investigators as ineligible to participate the study

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: PK Driven Prophylaxis for Hemophilia A

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male Patient~* Severe or moderately severe haemophilia A (FVIII = 2 %), preventively treated (processing) by ADVATE for at least 6 months,~* At last 6 years old,~* An informed consent must be signed by the patient or his legal representative for the patients minor.~* Affiliated to a national insurance scheme~Exclusion Criteria:~* Previous or actual treatment with FVIII inhibitors \> 0,6 UB at the selection~* Induction of immune tolerance~* Planned orthopedic surgery for the 18 next months~* Any other haemostatic pathology~* Any treatment interacting on the haemostasis~* Patient under guardianship~* Patient participating in another biomedical research

- Gender: MALE
- Minimum Age: 6 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- MyPKFiT (Type: EXPERIMENTAL): Personalized prophylaxis : Treatment is adjustment according to PK modeling

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: A Research Study to Evaluate Safety and Efficacy of DUR-928 in Subjects With Primary Sclerosing Cholangitis (PSC)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Verified diagnosis of primary sclerosing cholangitis (PSC) for at least 12 months, with or without inflammatory bowel disease (IBD).~* Serum alkaline phosphatase (ALP) ≥ 1.5 times ULN and with no \>15% fluctuation in the past 3 months.~* In subjects receiving treatment with ursodeoxycholic acid (UDCA), therapy must be stable for at least 3 months and at a dose not greater than 20 mg/kg/day.~* Subjects of childbearing potential must agree to use a medically acceptable method of contraceptive to prevent pregnancy in the subject and/or the partner for the duration of their participation in the trial up to 2 months after the last study drug dosing.~Exclusion Criteria:~* Presence of documented secondary sclerosing cholangitis or small duct PSC~* Bacterial cholangitis within 30 days prior to Screening~* Presence of percutaneous drain or endoscopic bile duct stent~* History of, or suspicion of cholangiocarcinoma.~* Prior liver transplantation, or currently listed for liver transplantation~* Presence of other concomitant liver diseases~* Moderate to Severe active IBD or flare in colitis activity within the last 3 months~* Any severe and/or untreated concomitant cardiovascular, renal, endocrine or psychiatric disorder~* Any active malignant disease (within 3 years), other than non-melanomatous skin cancer~* Human immunodeficiency virus (HIV) infection~* Existing or intended pregnancy, or breast feeding~* Has received medication from another clinical trial within the past 30 days

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- DUR-928 10 mg (Type: EXPERIMENTAL): 10 mg oral suspension
- DUR-928 50 mg (Type: EXPERIMENTAL): 50 mg oral suspension

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues